Sanofi-Aventis announces R&D restructuring

Share this article:
Sanofi-Aventis announced plans to restructure its R&D model, set to be completed by 2013. 

No layoffs will result from the restructuring, according to the statement (pdf), although some 1,300 employees will be eligible for “voluntary departures,” according to the Wall Street Journal. Company locations in the UK, Japan and Spain will be closed, along with four sites in France, with a fifth being divested. 

Around 650 people will be shuffled into different locations or jobs in France, according to the statement.

“The objective of this new R&D model is to propose innovate solutions that respond to specific, unmet needs of patients and continue our success in a very competitive international environment, said Chris Viehbacher, CEO, in the statement.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union